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Abstract
Aims/hypothesis Hyperglycaemia and insulin resistance
have been linked to diastolic dysfunction experimentally.
We investigated the association between glucose metabolism
and diastolic function along the whole spectrum of glucose
metabolism states.
Methods In the observational Diagnostic Trial on Prevalence
and Clinical Course of Diastolic Dysfunction and Diastolic
Heart Failure (DIAST-CHF) study, patients with risk factors
for heart failure were included. We analysed data including
comprehensive echocardiographyfroma subgroupofpatients
classified by OGTT and history as normal (n=343), predia-
betic (n=229) and non-insulin treated (n= 3 3 5 )o ri n s u l i n -
treated (n=178) type 2 diabetic.
Results While ejection fraction did not differ, markers of
diastolic function significantly worsened across groups.
Prediabetes represented an intermediate between normal
glucose metabolism and diabetes with regard to echocardio-
graphy changes. Prevalence and severity of diastolic dysfunc-
tion increased significantly (p<0.001) along the diabetic
continuum. Glucose metabolism status was significantly
associated with prevalence of diastolic dysfunction on
multivariate logistic regression analysis. In the whole cohort,
HbA1c correlated with early diastolic mitral inflow velocity
(E):early diastolic tissue Doppler velocity at mitral annulus
(e′) ratio (E:e′)( r=0.20, p<0.001). HbA1c was significantly
associated with E:e′ on multivariate analysis. Similarly,
glucose metabolism status was significantly associated with
E:e′ on multivariate analysis. The distance walked in 6 min
decreased along the diabetic spectrum and was significantly
correlated with E:e′ and grade of diastolic dysfunction.
Conclusions/interpretation Glucose metabolism is associ-
ated with diastolic dysfunction across the whole spectrum.
Our data extend previous observations into the prediabetic
and normal range, and may be relevant to preventive
approaches, as no effective treatment has been identified for
diastolic heart failure once established.
Keywords Cross-sectional studies.Diabetes mellitus.
Diastolic heart failure.Echocardiography.Exercise
tolerance.Insulin resistance.Prediabetic state
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A Late diastolic mitral inflow velocity
a′ Late diastolic tissue Doppler velocity
(at mitral annulus)
CHF Chronic heart failure
DIAST-CHF Diagnostic Trial on Prevalence and Clinical
Course of Diastolic Dysfunction and
Diastolic Heart Failure
E Early diastolic mitral inflow velocity
e′ Early diastolic tissue Doppler velocity
(at mitral annulus)
FPG Fasting plasma glucose
FPI Fasting plasma insulin
HFnEF Heart failure with normal ejection fraction
1 h-PG 1 h plasma glucose
2 h-PG 2 h plasma glucose
2 h-PI 2 h plasma insulin
ISI(0,120) Insulin sensitivity index according to Gutt
LVMI Left ventricular mass index
PVS Systolic pulmonary vein flow velocity
PVD Diastolic pulmonary vein flow velocity
QUICKI Quantitative insulin sensitivity check index
S:D Ratio of PVS to PVD
Introduction
Chronic heart failure (CHF) is an ongoing epidemic of
growing dimensions in western societies [1]. It has been
recognised [2] and recently confirmed [3] that a large
percentage of patients presenting with the clinical syndrome
of heart failure have a normal left ventricular ejection
fraction. These cases are therefore termed ‘heart failure with
normal ejection fraction’ (HFnEF) and left ventricular
diastolic dysfunction is believed to be common in these
patients [4]. Once hospitalised for heart failure, their
prognosis is similarly grim to that of patients with ‘classic’
systolic heart failure [2, 3]. Randomised trials looking for
specific therapeutic interventions have been few and notori-
ously unsuccessful [5, 6]. Prevention therefore is of the
essence if HFnEF is to be dealt with at a population level.
Diabetes mellitus has also reached epidemic proportions
worldwide, with a further 50% increase in worldwide
prevalence projected to occur by 2025 [7]. While well
known as a strong risk factor for atherosclerotic disease, the
relationship between diabetes and incident heart failure has
as yet attracted less attention. Preclinical studies have
linked diabetes to abnormalities in left ventricular relaxa-
tion and compliance [8]. Clinically, a large proportion of
diabetic patients has been shown to have diastolic dysfunc-
tion [9] and diabetes is prevalent in patients with HFnEF
[10]. Insulin resistance, a state that is generally present
before the onset of type 2 diabetes, also seems to play a
major role [11].
Given the proposed association of insulin resistance with
diastolic dysfunction and the importance of preventive
approaches for HFnEF, we sought to better define the link
between glucose metabolism and diastolic dysfunction
across a wide spectrum of metabolic statuses ranging from
normal glucose metabolism through to prediabetes and
type 2 diabetes mellitus treated either less intensively, i.e.
without insulin (oral glucose-lowering therapy only), or
more intensively with a regimen including insulin. Insulin
treatment was used as a surrogate for more advanced
disease requiring more intensive treatment.
Methods
Participants The ongoing non-interventional DIAST-CHF
(Diagnostic Trial on prevalence and clinical course of
diastolic dysfunctionand diastolic heart failure) study, which
is part of the nationwide German Competence Network
Heart Failure project, included patients aged 50 to 85 years
with risk factors for diastolic heart failure (defined as history
of hypertension, diabetes mellitus, sleep apnoea syndrome or
atheroscleroticdisease)ormanifest CHF,definedasa history
of CHF or presence of at least one major and two minor
criteria according to the Framingham diagnostic criteria at
presentation [12]. Candidates were referred by primary care
physicians. As a population-based study, the only exclusion
criterion was inability to participate or consent due, for
example, to language problems, concomitant diseases or
geographic reasons. Participants underwent a comprehen-
sive non-invasive diagnostic workup at baseline, including
history and physical examination, laboratory analyses,
echocardiography, ECG, 6 min walk test and completion
of several psychosocial and quality of life questionnaires,
with additional tests performed in subsets of patients.
At the two study sites with the vast majority of
participants (Goettingen and Berlin, 1,728 participants
included out of 1,935 in the overall study), all patients
without a history of diabetes mellitus were offered an
OGTT. For the analyses presented here, all participants who
underwent OGTT at baseline were included, as well as
those who had been diagnosed with type 2 diabetes mellitus
before inclusion and/or were being treated with glucose-
lowering medication. Patients who were diagnosed with
diabetes before the age of 40 and who became insulin-
dependent within less than 1 year were considered to have a
high probability of suffering from type 1 diabetes and were
excluded from analyses.
The study complied with the Declaration of Helsinki, the
protocol was approved by the responsible Ethics Committee
and all patients gave written informed consent.
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for theOGTT. Fasting plasma glucose (FPG) was determined
immediately before ingestion of 75 g of solubilised glucose,
followed 1 and 2 h later by determination of 1 h plasma
glucose (1 h-PG) and 2 h plasma glucose (2 h-PG). Insulin
levelsweredeterminedasfastingplasmainsulin(FPI)and2h
after glucose load as 2 h plasma insulin (2 h-PI). Patients
were considered to have: (1) normal glucose metabolism at
fasting glucose <5.6 mmol/l and 2 h glucose <7.8 mmol/l;
(2)prediabetes when fastingglucosewas5.6 to 7.0mmol/lor
2 h glucose 7.8 to 11.1 mmol/l; and (3) diabetes mellitus at
fasting glucose >7.0 mmol/l or 2 h glucose >11.1 mmol/l, as
currently recommended by the American Diabetes Associa-
tion[13]. No OGTTwas performed on insulin-treated type 2
diabetic participants and very few participants with stable
type 2 diabetes treated by oral glucose-lowering medication
underwent testing.
Insulin was measured with a commercially available
immunoassay on an automated analyser (ADVIA Centaur;
formerlyBayerDiagnostics,nowpartofSiemensHealthCare
Diagnostics, Eschborn, Germany). HbA1c was measured in
EDTA blood on an automated analyser (Integra 800; Roche
Diagnostics, Mannheim, Germany) with a reference range of
2.9% to 4.2% according to recommendations of the
International Federation of Clinical Chemistry.
Echocardiography Echocardiography was performed on a
Sonos 5500 (Hewlett-Packard, Andover, MA, USA)
according to the guidelines of the American Society of
Echocardiography, including comprehensive evaluation of
diastolic function with Doppler and tissue Doppler tech-
niques. All examinations were performed by physicians
experienced in the technique. As DIAST-CHF is part of the
nationwide German Competence Network for Heart Failure
project, randomly chosen echo examinations were reviewed
by the echo core lab at the University of Essen for quality
assurance.
Dimensions were recorded by standard techniques.
Interventricular septum, left ventricular posterior wall
thickness, left ventricular end-diastolic diameter, and end-
systolic and left atrial diameter were measured by M-mode
or anatomically, as appropriate. Left ventricular end-
diastolic and end-systolic volumes, and ejection fraction
were determined by the modified uniplanar Simpson’s rule
in the majority of patients. Transmitral peaks of early
diastolic mitral inflow velocity (E), and late diastolic mitral
inflow velocity (A) and E wave deceleration time were
recorded at the tips of the mitral valve leaflets. Isovolu-
metric relaxation time was obtained in the apical five
chamber view. Doppler signals of systolic pulmonary vein
flow velocity (PVS), diastolic pulmonary vein flow velocity
(PVD) and atrial reverse pulmonary vein flow velocity were
recorded in the right upper pulmonary vein. Peak tissue
velocities were derived by tissue Doppler analysis at the
lateral margin of the mitral annulus for early diastolic tissue
Doppler velocity (e′) and late diastolic tissue Doppler
velocity (a′) inflow.
Calculations and statistical analyses As an estimate of
global glucose tolerance, the AUC for glucose over the 2 h
interval of the OGTT was calculated using a trapezoidal
approach for integration (AUCGlu0–120). To correct for FPG,
we normalised AUC by indexing to the integral of fasting
glucose over 2 h (AUCGlu0–120/[FPG×2]), reflecting the
relative increase in plasma glucose over the 2 h interval. As
surrogates for insulin sensitivity, HOMA and quantitative
insulin sensitivity check index (QUICKI) were calculated, as
well as the insulin sensitivity index according to Gutt
(ISI0,120), all as described and recommended previously [14].
Left ventricular mass index (LVMI) was calculated by
the Devereux formula indexed to body surface area [15].
For evaluation of diastolic function, we calculated the ratios
of E to A (E:A), of PVS to PVD (S:D), of E to e′ (E:e′) and
of e′ to a′ (e′:a′). Diastolic dysfunction was classified as
follows: (1) normal diastolic function with 1≤E:A, E:e′ <10,
S:D ≥1, E:A with Valsalva manoeuvre ≥1; (2) mild diastolic
dysfunction with E:A<1; (3) moderate diastolic dysfunction
with 1≤E:A<2, and one of E:e′ ≥10, S:D <1 and E:A
Valsalva <1; and (4) severe diastolic dysfunction with E:A
≥2, and one of E:e′ ≥10 and S:D <1.
Descriptive statistics were performed stratified by glucose
metabolism status. Several variables were not normally
distributed. Therefore, data are expressed as median (inter-
quartile range) for continuous variables or absolute number
(per cent) for categorical. Log-transformed values were used
for some analyses as appropriate. Non-parametric tests for
group differences between categories of glucose tolerance
were performed. The Jonckheere–Terpstra test is most
sensitive for detection of effects across ordered categories.
For comparison of proportions, Armitage’s test for trend was
applied. To investigate relations between variables, bivariate
correlations were calculated. We used multivariate analysis
of covariances and logistic regression to unravel multivariate
relationships.
Statistical analyses were performed with SPSS Statistics
15.0 software (SPSS, Chicago, IL, USA).
Results
Patient characteristics Of 1,935 patients included in
DIAST-CHF, 1,085 patients were analysed, of whom 637
had an OGTT. A minority of these (13 patients) had a
previous diagnosis of type 2 diabetes mellitus and were
being treated with glucose-lowering medication. Overall,
465 patients had a history of diabetes mellitus at inclusion,
Diabetologia (2010) 53:1331–1340 1333of whom four with probable type 1 diabetes were excluded
from analyses. Of the remaining 461 patients with known
type 2 diabetes mellitus, 178 were treated with insulin and
283 with diet and/or oral glucose-lowering drugs.
Among those undergoing glucose tolerance testing, 343
participants (55.0%) had normal glucose metabolism, 229
(36.7%) had prediabetes and 52 (8.3%) had newly
diagnosed diabetes mellitus (Fig. 1).
Clinical characteristics for patients with normal, predia-
betic and diabetic glucose metabolism are shown in Table 1.
Glucose and lipid metabolism variables are shown in
Table 2. Overall, prediabetes tended to be an intermediate
stage between normal and diabetic groups with regard to
many indicators of metabolic disturbance and end-organ
disease, while patients with insulin-treated type 2 diabetes
had the highest rates of end-organ disease or comorbidities.
Groups did not differ with regard to age, systolic blood
pressure and prevalence of hypertension. Patients with
diabetes were treated more intensively than those with
prediabetes or normal glucose metabolism. Treatments were
with typical cardiovascular drugs with a significant trend
towards ACE inhibitors, loop diuretics, aldosterone antago-
nists,statins,acetylicsalicylic acidandvitaminKantagonists.
Consistent with the process of group allocation,
prediabetic participants had significantly higher FPI and
FPG than non-diabetic participants, as well as higher 1 h-PG
and 2 h-PG, reflected also in AUCGlu0–120 and normalised
AUCGlu0–120. Insulin resistance as approximated by
HOMA was higher, and insulin sensitivity as approximated
by QUICKI and Gutt index lower in prediabetic partic-
ipants. Prediabetes also displayed an intermediate state in
between normal and type 2 diabetic patients on oral
glucose-lowering medication. LDL-cholesterol was para-
doxically lower in this group and in insulin-treated type 2
diabetic patients, while HDL-cholesterol decreased with
severity of glucose metabolism disturbance. This phe-
nomenon is probably due to the fact that LDL-cholesterol
is effectively lowered by statin therapy, which was more
prevalent in diabetic patients, while low HDL-cholesterol
is less amenable to pharmacological treatment.
Prevalence of diastolic dysfunction Diastolic function
could not be analysed or classified in 61 participants
(5.6%) due to presence of atrial fibrillation or missing
echocardiographic variables critical for classification. Ac-
cordingly, 1,024 participants were included in the analysis
of diastolic function. Echocardiographic variables are listed
in Table 3.
Prevalence of any degree of diastolic dysfunction
increased with impairment in glucose metabolism, i.e. the
highest prevalence was found among insulin-treated type 2
diabetic patients (87.3%) or those on oral glucose-lowering
therapy (88.4%) as compared with those with prediabetes
(86.7%) or normal glucose metabolism (76.0%, p<0.001
test for trend). Participants with prediabetes represented an
intermediate between normal (p=0.009 for difference) and
diabetic patients with regard to diastolic dysfunction. This
is also evidenced by trends in structural variables that are
indicative of diastolic dysfunction, but not used as criteria
for classification, e.g. left atrial diameter or LVMI. While
prevalence of diastolic dysfunction of any grade was very
similar between prediabetes and diabetes, the distribution
across grades 1 to 3 of diastolic dysfunction was shifted to
the right for diabetes as compared with prediabetes (Fig. 2),
reflected by a statistically significant χ
2 test of the
correspondent 3 × 4 table (p<0.001). Only a small number
of patients were identified as having severe diastolic
dysfunction, none of whom had normal glucose metabo-
lism; therefore patients with moderate or severe diastolic
dysfunction were placed in one group for the above
analysis.
Status of glucose metabolism remained significantly
associated with prevalence of diastolic dysfunction in
logistic regression analysis adjusted for the significantly
associated variables heart rate, systolic blood pressure, and
presence or history of heart failure. Furthermore, an odds
ratio of 1.77 (95% CI 1.10–2.86) for having diastolic
dysfunction was estimated for the prediabetes group
compared with the normal glucose metabolism group.
Impairment in glucose metabolism and severity of diastolic
dysfunction As a functional variable indicative of left
ventricular end-diastolic pressure, E:e′ was similar in
prediabetes compared with normal glucose metabolism,
but was significantly higher (p=0.002) in diabetes than in
the other groups. In the whole cohort, E:e′ correlated
significantly with HbA1c (r=0.20, p<0.001), as well as
Fig. 1 Glucose metabolism among participants of OGTT. White,
normal glucose; light grey, prediabetes; dark grey, newly diagnosed
type 2 diabetes; black, known type 2 diabetes treated with oral
glucose-lowering medication
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2 h-PI, normalised AUCGlu0–120 and ISI0,120. Importantly,
the association between E:e′ and HbA1c remained signifi-
cant when including only patients with HbA1c in the normal
range, i.e. ≤4.2% (r=0.16, p<0.05).
In multivariate linear analysis including sex, CHD,
CHF, history of myocardial infarction, age, log(BMI),
heart rate, systolic and diastolic blood pressure, cardio-
vascular medications and HbA1c as predictors, HbA1c
remained significantly (p<0.001) associated with log(E:e′).
When modelling status of glucose metabolism in place of
HbA1c in a general linear model with log (E:e′)a s
dependent variable, status of glucose metabolism was a
significant predictor, together with sex, age, log (BMI),
heart rate, systolic and diastolic blood pressure, and both
beta blocker and aldosterone antagonist intake. These
associations remained significant with Bonferroni–Holm
adjustment for multiple testing.
LVMI and left atrial diameter as structural markers of
diastolic function correlated significantly with HbA1c
Table 1 Clinical characteristics of patients with normal, prediabetic or diabetic glucose metabolism
Variable Normal Prediabetes DM2 oral DM2 insulin p value
a
n 343 229 335 178
Measured variables
Age (years) 66.0 (61.2–71.0) 67.0 (62.0–72.0) 66.0 (61.0–72.0) 65.5 (61.0–71.0) 0.573
Female sex, n (%) 181 (52.8) 105 (45.9) 130 (38.8) 86 (48.3) 0.025
BMI (kg/m
2) 27.0 (24.8–29.4) 29.0 (26.7–31.7) 29.4 (27.1–33.2) 31.2 (27.5–34.7) 0.000
b
WHR 0.92 (0.86–0.98) 0.95 (0.90–1.01) 0.96 (0.90–1.01) 0.95 (0.95–1.02) 3.80E−09
b
Systolic BP (mmHg) 144 (132–160) 153 (139–168) 150 (136–165) 145 (130–161) 0.610
Diastolic BP (mmHg) 85 (76–92) 85 (79–94) 83 (78–90) 79 (70–85) 4.05E−05
b
Heart rate (beats per min) 63 (56–69) 64 (58–73) 67 (60–77) 67 (61–76) 0.000
b
6 min walk distance (m) 550 (496–600) 542 (485–600) 506 (425–570) 470 (394–537) 1.60E−20
b
Cardiovascular risk factors
Hypertension, n (%) 300 (87.5) 210 (91.7) 287 (85.7) 156 (87.6) 0.569
Hyperlipidaemia, n (%) 136 (39.7) 92 (40.2) 166 (49.6) 104 (58.4) 1.13E−05
b
Smoker, n (%) 44 (12.8) 12 (5.2) 38 (11.3) 19 (10.4) 0.051
CHD, n (%) 57 (16.6) 41 (17.9) 75 (22.4) 63 (35.4) 3.68E−06
b
Peripheral artery disease, n (%) 11 (3.2) 9 (3.9) 19 (5.7) 31 (17.4) 6.28E−08
b
Cerebrovascular disease, n (%) 26 (7.6) 14 (6.1) 35 (10.4) 13 (7.3) 0.488
CHF, n (%) 34 (9.9) 36 (15.7) 64 (19.1) 54 (17.3) 9.51E−09
b
Sleep apnoea, n (%) 20 (5.8) 14 (6.1) 24 (7.2) 23 (12.9) 0.011
Atrial fibrillation, n (%) 24 (7.0) 13 (5.7) 23 (6.9) 16 (9.0) 0.468
Medications
ACE-inhibitor, n (%) 146 (42.9) 101 (44.3) 165 (50.0) 108 (60.7) 1.43E−04
b
AT1 receptor antagonist, n (%) 50 (14.7) 33 (14.5) 58 (17.6) 43 (24.2) 0.009
Beta-blocker, n (%) 156 (45.9) 116 (50.9) 150 (45.5) 106 (59.6) 0.042
Thiazide diuretic, n (%) 129 (37.9) 106 (46.5) 138 (41.8) 73 (41.0) 0.510
Loop diuretic, n (%) 19 (5.6) 18 (7.9) 48 (14.5) 55 (30.9) 4.77E−15
b
Other diuretic, n (%) 10 (2.9) 13 (5.7) 17 (5.2) 8 (4.5) 0.304
Aldosterone antagonist, n (%) 2 (0.6) 1 (0.4) 6 (1.8) 7 (3.9) 0.003
b
Calcium antagonist, n (%) 63 (18.5) 41 (18.0) 85 (25.8) 47 (26.4) 0.007
Statin, n (%) 74 (21.8) 55 (24.1) 119 (36.1) 105 (59.0) 2.92E−17
b
Acetylic salicylic acid, n (%) 112 (32.9) 66 (28.9) 115 (34.8) 93 (52.2) 1.49E−04
b
Vitamin K antagonist, n (%) 13 (3.8) 12 (5.3) 27 (8.2) 17 (9.6) 0.003
b
Oral glucose-lowering, n (%) 0 (0) 0 (0) 214 (64.8) 52 (29.2) 1.40E−51
b
Values are median (interquartile range) or n (%)
aJonckheere–Terpstra test or Armitage’s test of trend for proportions, as appropriate;
bsignificant after Bonferroni–Holm adjustment (m=72)
DM2 insulin, insulin-treated type 2 diabetes; DM2 oral, type 2 diabetes on oral glucose-lowering medication
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E:e′, these structural variables also correlated with FPG
and FPI. However, in multivariate analysis associations of
LVMI and left atrial diameter with HbA1c lost signifi-
cance. Interestingly, there was also a highly significant
negative correlation of HDL-cholesterol with left atrial
diameter and LVMI. No significant correlation of struc-
tural variables with HbA1c was observed in patients with
HbA1c ≤4.2%. Nevertheless, when including only patients
with normal glucose metabolism or prediabetes, the
above-mentioned correlations remained statistically sig-
nificant except those between left atrial diameter and
HbA1c, and LVMI and 2 h-PG or HbA1c, respectively.
While the two type 2 diabetes treatment groups (oral
glucose-lowering medication, insulin) had a similar prev-
alence of diastolic dysfunction and similar distribution
across grades of diastolic dysfunction, E:e′ was signifi-
cantly higher in the insulin-treated than in the other group
(10.7 vs 9.5, p<0.05).
E:e′, left atrial diameter or LVMI did not correlate with
duration of diabetes or daily insulin dose.
Diabetes, diastolic dysfunction and physical impairment
The distance walked in 6 min as a simple indicator of
exercise capacity decreased along the diabetic continuum
(Table 1). Both grade of diastolic dysfunction (r=−0.29,
p<0.001) and E:e′ (r=−0.17, p<0.001) correlated signifi-
cantly with the distance walked in 6 min. Ejection fraction
did not differ significantly between groups and there was
only a very weak correlation between ejection fraction and
distance walked in 6 min (r=0.09, p<0.01).
Discussion
It has been reported previously that a large proportion of
diabetic patients have diastolic dysfunction [9], which is
believed to be a key component of diabetic cardiomyopathy
[16].
Our data confirm and extend these observations, as
prevalence of diastolic dysfunction was increased not only
in type 2 diabetic, but also in prediabetes participants.
Moreover, prevalence and severity of diastolic dysfunction
Table 2 Metabolic characteristics of patients with normal, prediabetic or diabetic glucose metabolism
Variable Normal Prediabetes DM2 oral DM2 insulin p value
a
n 343 229 335 178
HbA1c (%) 3.7 (3.1–4.1) 4.2 (3.8–4.6) 4.9 (4.4–5.5) 5.3 (4.9–6.1) 0.000
b
FPI (pmol/l) 44.4 (31.9–72.2) 75.7 (43.8–111.8) 93.1 (43.8–136.1) – 2.60E−14
b
2 h-PI (pmol/l) 374.3 (211.8–613.2) 598.7 (343.0–2,382.7) 898.0 (446.6–1,494.6) – 4.21E−15
b
FPG (mmol/l) 5.1 (4.8–5.3) 5.7 (5.6–6.0) 7.0 (6.1–7.5) – 0.000
b
1h-PGe (mmol/l) 7.7 (6.3–9.0) 10.2 (8.9–11.6) 14.3 (12.8–15.5) – 0.000
b
2h-PG (mmol/l) 5.6 (4.8–6.4) 7.8 (6.3–8.8) 12.2 (11.3–13.9) – 0.000
b
Glucose AUC (mmol l
−1×h) 12.9 (11.3–14.7) 16.9 (15.0–18.6) 23.8 (21.5–25.7) – 0.000
b
Glucose AUC normalised 1.30 (1.14–1.45) 1.50 (1.29–1.65) 1.73 (1.58–1.92) – 0.000
b
HOMA-IR index 1.40 (0.99–2.41) 2.62 (1.59–4.22) 3.77 (1.88–6.00) – 0.000
b
QUICKI 0.36 (0.33–0.38) 0.33 (0.31–0.36) 0.31 (0.30–0.35) – 1.52E−23
b
Gutt ISI1,20 4.4 (3.6–5.5) 3.1 (2.6–3.7) 1.9 (1.7–2.4) – 2.94E−55
b
Diabetes duration (years) –– 4( 1 –7.3) 13 (6.8–20.0) 0.000
b
Insulin-dependent for (years) –– – 4 (2.0–8.5) –
Daily total dose insulin (IE) –– – 48 (34–76) –
Total cholesterol (mmol/l) 5.4 (4.7–6.0) 5.3 (4.8–6.1) 4.9 (4.3–5.6) 4.7 (3.9–5.1) 6.09E−16
b
LDL-cholesterol (mmol/l) 3.3 (2.8–3.9) 3.4 (3.0–4.0) 3.0 (2.6–3.7) 2.7 (2.1–3.1) 2.97E−22
b
HDL-cholesterol (mmol/l) 1.4 (1.2–1.7) 1.4 (1.1–1.6) 1.2 (1.0–1.5) 1.1 (1.0–1.5) 2.88E−16
b
Uric acid (mmol/l) 5.8 (4.9–6.7) 6.3 (5.4–7.2) 6.3 (5.5–7.2) 6.1 (5.2–7.3) 3.19E−05
b
eGFR (ml min
−1 1.73 m
−2) 71.2 (63.3–78.9) 74.6 (64.2–86.5) 71.6 (63.5–88.0) 71.4 (60.1–78.5) 0.484
Values are median (interquartile range) or n (%)
aJonckheere–Terpstra test;
bsignificant after Bonferroni–Holm adjustment (m=72)
DM2 insulin, insulin-treated type 2 diabetes; DM2 oral, type 2 diabetes on oral glucose-lowering medication; eGFR, estimated GFR; IR, insulin
resistance
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metabolism along the whole spectrum of metabolic states. It
is noteworthy that we found a very high absolute
prevalence of diastolic dysfunction even in participants
with normal glucose metabolism compared with older
series [9, 17]. This, however, is not so surprising,
considering the design of DIAST-CHF, which includes
only patients with a risk factor for diastolic heart failure or
(a minority) with manifest CHF. The high prevalence may
also be due to the higher sensitivity of current echocardio-
graphic techniques, as well as to our classification, which
applies rather sensitive criteria for low-grade diastolic
dysfunction. Even so, we were able to show an association
between glucose metabolism and diastolic dysfunction.
With comprehensive echocardiographic characterisation
of a large group of participants with prediabetes, we were
able to show that prediabetes represents a morphological
intermediate between normal and diabetic states. Also, we
found significant trends for several indicators of diastolic
dysfunction along the type 2 diabetic continuum, pointing
to a graded effect of impaired glucose metabolism on
diastolic function, although such an interpretation is limited
by the cross-sectional nature of our analysis. Several
mechanisms for a conditional relationship between glucose
metabolism and diastolic function have been proposed.
Hyperinsulinaemia can lead to increased myocardial mass
through its growth-stimulating function and probably
differential organ-specific levels of insulin resistance [18].
Furthermore, hyperinsulinaemia leads to chronic sympathetic
nervous system activation with detrimental consequences on
the heart [19]. These observations suggest a theoretical basis
for our observation of subtle changes in myocardial,
specifically diastolic, function in prediabetes. Recently, it
was shown that insulin resistance was a predictor for
incident heart failure independently of diabetes [11].
Impaired insulin sensitivity and hyperinsulinaemia are often
Table 3 Echocardiographic characteristics of patients with normal, prediabetic or diabetic glucose metabolism
Variable Normal Prediabetes DM2 oral DM2 insulin p value
a
n 343 229 335 178
LVEDD (mm) 49 (45–52) 50 (46–53) 51 (46–53) 51 (46–54) 0.005
LVESD (mm) 30 (26–34) 30 (27–34) 31 (27–36) 32 (28–37) 3.16E−05
b
LVEDV (ml) 88.0 (71–106) 92.0 (78–113) 94.0 (76–116) 90.0 (74–110) 0.057
LVESV (ml) 35.0 (27–43) 37.0 (29–47) 37.0 (28–50) 36.0 (28–49) 0.030
LV-EF (%) 60 (55–65) 60 (54–65) 60 (55–65) 60 (54–64) 0.179
IVS (mm) 12 (11–13) 12 (11–13) 13 (11–14) 13 (11–14) 9.14E−05
b
LVPW (mm) 11 (10–12) 11 (10–12) 12 (11–13) 12 (11–13) 2.73E−08
b
LVMI (g/m
2) 113.9 (97.8–130.9) 116.5 (101.3–133.2) 121.2 (102.0–141.6) 120.6 (100.2–140.0) 0.002
LAD (mm) 40 (37–45) 42 (38–45) 43 (38–46) 43 (40–47) 3.88E−08
b
E (cm/s) 71 (59–83) 73 (60–84) 70 (58–82) 73 (62–89) 0.046
A (cm/s) 77 (65–89) 82 (69–93) 82 (70–95) 83 (69–102) 1.97E−05
b
E:A ratio 0.88 (0.74–1.13) 0.86 (0.72–1.12) 0.83 (0.69–1.05) 0.83 (0.70–1.14) 0.008
Deceleration time (ms) 240 (202–298) 240 (195–300) 256 (201–305) 244 (195–300) 0.812
IVRT (ms) 100 (90–119) 100 (90–117) 105 (90–120) 97 (85–115) 0.559
e′ (cm/s) 7.9 (6.5–9.5) 7.9 (6.3–9.3) 7.6 (6.0–9.0) 7.0 (5.5–8.9) 0.008
a′ (cm/s) 11.2 (9.3–13.0) 11.0 (9.4–12.8) 11.0 (9.6–13.0) 11.0 (9.1–13.1) 0.760
e′:a′ 0.70 (0.55–0.90) 0.70 (0.55–0.90) 0.64 (0.55–0.85) 0.63 (0.47–0.83) 0.009
E:e′ 9.0 (7.3–11.2) 8.9 (7.3–11.5) 9.5 (7.4–11.8) 10.7 (8.3–13.7) 1.26E−04
b
PVS (cm/s) 63 (54–73) 63 (55–71) 61 (54–69) 60 (51–70) 0.003
PVD (cm/s) 44 (37–52) 45 (37–53) 43 (37–51) 45 (37–54) 0.798
PVA (cm/s) 30 (27–33) 30 (27–33) 30 (26–33) 29 (26–32) 0.066
S:D ratio 1.41 (1.21–1.66) 1.41 (1.20–1.67) 1.40 (1.18–1.67) 1.38 (1.12–1.61) 0.118
Values are median (interquartile range)
aJonckheere–Terpstra test;
bsignificant after Bonferroni–Holm adjustment (m=72)
IVRT, isovolumetric relaxation time; IVS, interventricular septum; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter;
LVEDV, left ventricular end-diastolic volume; LV-EF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESV, left
ventricular end-systolic volume; LVPW, left ventricular posterior wall; PVA, atrial reverse pulmonary vein flow velocity
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Also, insulin sensitivity and levels are continuous (rather
than discrete) traits, making a continuous and graded effect
intuitively more plausible than a threshold constellation.
Similarly, hyperglycaemia has been linked to alterations in
myocardial calcium handling and extracellular matrix
modifications, leading to increased ventricular stiffness and
impaired relaxation [8]. Indeed, across the whole cohort,
HbA1c was independently associated with E:e′, a variable
that strongly correlates with left ventricular end diastolic
pressure [20] and with the presence of diastolic dysfunction.
We even found some evidence for such an association in the
subgroup with normal glucose metabolism. HbA1c as a con-
tinuous variable incorporates glucose levels over a longer
period of time and can therefore be considered a more stable
indicator of plasma glucose status, which is less vulnerable
to acute perturbations around the time of testing. In fact, for
these very reasons HbA1c has recently been suggested for
use as a primary variable on which to base the diagnosis of
diabetes [21]. The correlation of E:e´ with HbA1c comple-
ments data showing that in diabetic patients a 1% increase in
HbA1c is associated with an increase in the risk of heart
failure of between 8 and 32% [22–24]. Similarly, FPG has
recently been shown to be prognostic of incident heart
failure in a very large randomised trial of patients at high
cardiovascular risk [25]. Our data strengthen the experi-
mentally based assumption that a considerable part of the
increased risk of heart failure in diabetes is due to
impaired diastolic function linked to hyperinsulinaemia
and hyperglycaemia.
The observed elevation in E:e′ can be assumed to be of
prognostic relevance, as an E:e′ >15 resulted in an 11%
relative increase in all-cause mortality rates in a recent
retrospective analysis of diabetic patients from Olmsted
county [26]. Similarly, degree of diastolic dysfunction was
an independent predictor of all-cause mortality in a large
epidemiological study [9].
Statistically speaking, the biological signal we found is
not very strong against the ‘noise’ in our heterogeneous
population-based cohort; the model fitting also leaves
something to be desired. However, the observed association
may still be of considerable importance at a population
level, considering the epidemic proportions of diabetes and
the persistent lack of effective treatments for diastolic
dysfunction and diastolic heart failure.
Exercise capacity, as measured by 6 min walk test,
decreased along the diabetic continuum. Although this may
in part reflect more activity-limiting comorbidities, we also
observed a highly significant negative correlation between
E:e´ and distance walked in 6 min in our sample, indicating
that impaired exercise capacity may be partly due to
diastolic dysfunction. It has previously been demonstrated
in a small sample that decreased exercise tolerance is
associated with diastolic dysfunction in patients with
diabetes, even when well controlled and without CHD,
hypertension or heart failure [27, 28]. Our results extend
these data to a broader population and a much larger
sample. In contrast to diastolic dysfunction, left ventricular
ejection fraction did not differ across groups of glucose
metabolism and was only very weakly associated with
distance walked in 6 min.
Our data show that diastolic dysfunction is partly deter-
mined by glucose metabolism even in participants with
normal glucose and those with prediabetes, thus supporting
early preventive measures to improve glucose metabolism on
a population scale as one possible approach to combat
diastolic dysfunction and diastolic heart failure. Although
we cannot directly draw such conclusions from our cross-
sectional and non-interventional study, improvements in
diastolic function with intensified glucose control have
been demonstrated in diabetic patients [29], providing the
theoretical basis for such a demand. The relevance of
glucose metabolism for diastolic dysfunction in a longitudi-
nal setting will be the subject of future analyses from
DIAST-CHF.
With regard to technicalities, clear strengths of our study
include its well characterised sample of patients with all
stages of impairment of glucose metabolism. As all non-
diabetic participants underwent OGTT, allocation to the
respective group was exact. In addition, the measurement of
HbA1c in the majority of patients adds further detail to the
metabolic characterisation of our patients. Diastolic dys-
function was analysed with tissue Doppler techniques that
were considered state-of-the-art at the time of data
collection and indeed more advanced than those used by
most published studies on the subject.
Several aspects of our report, however, merit critical
review. As this analysis was cross-sectional, no conclusions
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Fig. 2 Severity of diastolic dysfunction (DD) among patients with
normal glucose metabolism, prediabetes, and type 2 diabetes (DM2)
treated by insulin or by oral glucose-lowering medication. Dotted
white bars, normal DD; light grey, mild DD; hatched, moderate DD;
black, severe DD
1338 Diabetologia (2010) 53:1331–1340on causality can be drawn. We did not limit our analysis to
participants without overt cardiovascular disease like
coronary artery disease or CHF, as is often done in studies
investigating diabetic cardiomyopathy. This approach was
chosen to assess the overall relationship of glucose
metabolism with diastolic function, be it independent or
be it mediated through end-organ disease. The fact that the
associations remained significant when including coronary
artery disease and CHF as covariates in the respective
models indicates that glucose metabolism plays a role
independently of coronary artery disease and CHF as
mediating factors. Grading of diastolic dysfunction is the
subject of an ongoing debate and newer guidelines have
been published [30], whose clinical value has yet to be
prospectively validated. It would have been interesting to
measure fasting triacylglycerol, considering the recently
proposed role of myocardial triacylglycerol accumulation in
diabetic cardiomyopathy [31]. We did, however, observe a
significant correlation between markers of diastolic dys-
function and low HDL-cholesterol levels. As the latter are
part of the typical pattern of dyslipidaemia with low HDL-
cholesterol and elevated triacylglycerol most frequently
observed in insulin resistance, this might provide some
indirect evidence. Similarly, it would also have been
interesting to include a larger group of patients with
confirmed type 1 diabetes or to determine diabetes-
associated antibodies for diagnosis of latent autoimmune
diabetes in adults, as this might have allowed us to
speculate on whether divergent underlying pathophysiol-
ogies could have had a differential impact on diastolic
function. Given our observations, we were rather surprised
that duration of type 2 diabetes did not correlate with E:e′
or other markers of diastolic function. We speculate that
duration of type 2 diabetes does not necessarily reflect
severity of disease. The latter might be more appropriately
indicated by HbA1c, which reflects glycaemia over a period
of time, and by the use of insulin, which reflects the
necessity for intensified treatment in most cases.
In summary, our data show an association between
diastolic dysfunction and glucose metabolism along the
diabetic continuum, which extends into the normal range.
Diastolic dysfunction negatively correlates with exercise
tolerance. Our analysis supports a relevant role for diastolic
dysfunction in diabetic heart failure and also the initiation
of early preventive measures to address diastolic heart
failure in the community.
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